Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome (Q40568751)

21 September 2017

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome (English)

1 reference

21 September 2017

0 references

0 references

schizophrenic prodrome

1 reference

11

Thomas H McGlashan

1 reference

21 September 2017

5

Jean Addington

1 reference

21 September 2017

Scott W Woods

1

1 reference

21 September 2017

Alan Breier

2

1 reference

21 September 2017

Robert B Zipursky

3

1 reference

21 September 2017

Diana O Perkins

4

1 reference

21 September 2017

Tandy J Miller

6

1 reference

21 September 2017

Keith A Hawkins

7

1 reference

21 September 2017

Eva Marquez

8

1 reference

21 September 2017

Stacy R Lindborg

9

1 reference

21 September 2017

Mauricio Tohen

10

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

21 September 2017

Biological Psychiatry

1 reference

21 September 2017

54

1 reference

21 September 2017

453-464

1 reference

21 September 2017

4

1 reference

A rating scale for drug-induced akathisia

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

West London first-episode study of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of untreated psychosis predicts treatment outcome in an early psychosis program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Deficit states in schizophrenia and their association with the length of illness and gender

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Putatively psychosis-prone subjects 10 years later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A randomised controlled trial of prophylactic neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of untreated psychosis and the long-term course of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Causes and consequences of duration of untreated psychosis in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Early intervention for first episodes of schizophrenia: a preliminary exploration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Features of structural brain abnormality detected in first-episode psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Global assessment of functioning. A modified scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Factorial structure of the Scale of Prodromal Symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The positive and negative syndrome scale (PANSS) for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Diagnosing schizophrenia in the initial prodromal phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Olanzapine-associated diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A ten-year follow-up study of Chinese schizophrenics in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Duration of psychosis and outcome in first-episode schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Accounting for dropout bias using mixed-effects models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Type I Error Rates from Mixed Effects Model Repeated Measures versus Fixed Effects Anova with Missing Values Imputed via Last Observation Carried Forward

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Schizophrenia. A follow-up study of the results of five forms of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Psychosis treatment prior to psychosis onset: ethical issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Early detection and intervention with schizophrenia: rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

EPPIC: an evolving system of early detection and optimal management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Symptom assessment in schizophrenic prodromal states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A New Depression Scale Designed to be Sensitive to Change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Risk factors of psychosis: identifying vulnerable populations premorbidly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Treatment histories of patients with a syndrome putatively prodromal to schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Outcome study of first-episode psychosis. I: Relapse rates after 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Preventing severe mental illnesses--new prospects and ethical challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Schizophrenia researchers striving for early detection and intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Course of treatment response in first-episode and chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Effects of development on olanzapine-associated adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The "prodromal" patient: both symptomatic and at-risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Neuroleptics and the Natural Course of Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

A rating scale for mania: reliability, validity and sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

The initial prodrome in psychosis: descriptive and qualitative aspects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900321-4

10.1016/S0006-3223(03)00321-4

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference